Open versus laparoscopically-assisted oesophagectomy for cancer: a multicentre randomised controlled phase III trial - the MIRO trial. - Inserm - Institut national de la santé et de la recherche médicale Accéder directement au contenu
Article Dans Une Revue BMC Cancer Année : 2011

Open versus laparoscopically-assisted oesophagectomy for cancer: a multicentre randomised controlled phase III trial - the MIRO trial.

Franck Bonnetain
  • Fonction : Auteur
  • PersonId : 907734
Cécile Brigand
  • Fonction : Auteur
  • PersonId : 907735
Denis Collet
  • Fonction : Auteur
  • PersonId : 907737
Christophe Doddoli
  • Fonction : Auteur
  • PersonId : 907738
Renaud Flamein
  • Fonction : Auteur
  • PersonId : 907739
Jean-Yves Mabrut
  • Fonction : Auteur
  • PersonId : 907740
Simon Msika
  • Fonction : Auteur
  • PersonId : 907741
Thierry Perniceni
  • Fonction : Auteur
  • PersonId : 907742
Michel Prudhomme
  • Fonction : Auteur
  • PersonId : 907744

Résumé

UNLABELLED: ABSTRACT: BACKGROUND: Open transthoracic oesophagectomy is the standard treatment for infracarinal resectable oesophageal carcinomas, although it is associated with high mortality and morbidity rates of 2 to 10% and 30 to 50%, respectively, for both the abdominal and thoracic approaches. The worldwide popularity of laparoscopic techniques is based on promising results, including lower postoperative morbidity rates, which are related to the reduced postoperative trauma. We hypothesise that the laparoscopic abdominal approach (laparoscopic gastric mobilisation) in oesophageal cancer surgery will decrease the major postoperative complication rate due to the reduced surgical trauma. METHODS/DESIGN: The MIRO trial is an open, controlled, prospective, randomised multicentre phase III trial. Patients in study arm A will receive laparoscopic-assisted oesophagectomy, i.e., a transthoracic oesophagectomy with two-field lymphadenectomy and laparoscopic gastric mobilisation. Patients in study arm B will receive the same procedure, but with the conventional open abdominal approach. The primary objective of the study is to evaluate the major postoperative 30-day morbidity. Secondary objectives are to assess the overall 30-day morbidity, 30-day mortality, 30-day pulmonary morbidity, disease-free survival, overall survival as well as quality of life and to perform medico-economic analysis. A total of 200 patients will be enrolled, and two safety analyses will be performed using 25 and 50 patients included in arm A. DISCUSSION: Postoperative morbidity remains high after oesophageal cancer surgery, especially due to major pulmonary complications, which are responsible for 50% of the postoperative deaths. This study represents the first randomised controlled phase III trial to evaluate the benefits of the minimally invasive approach with respect to the postoperative course and oncological outcomes in oesophageal cancer surgery. TRIAL REGISTRATION: NCT00937456 (ClinicalTrials.gov).
Fichier principal
Vignette du fichier
1471-2407-11-310.pdf (268.41 Ko) Télécharger le fichier
1471-2407-11-310.xml (50.86 Ko) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte
Format : Autre
Loading...

Dates et versions

inserm-00614725 , version 1 (15-08-2011)

Identifiants

Citer

Nicolas Briez, Guillaume Piessen, Franck Bonnetain, Cécile Brigand, Nicolas Carrere, et al.. Open versus laparoscopically-assisted oesophagectomy for cancer: a multicentre randomised controlled phase III trial - the MIRO trial.. BMC Cancer, 2011, 11 (1), pp.310. ⟨10.1186/1471-2407-11-310⟩. ⟨inserm-00614725⟩
247 Consultations
309 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More